Details for New Drug Application (NDA): 214512
✉ Email this page to a colleague
NDA 214512 describes ALENDRONATE SODIUM, which is a drug marketed by Hikma, Novitium Pharma, Apotex, Aurobindo Pharma, Chartwell Rx, Cipla, Hangzhou Binjiang, Impax Labs Inc, Ipca Labs Ltd, Jubilant Cadista, Mylan, Rising, Sun Pharm, Teva Pharms, and Watson Labs, and is included in sixteen NDAs. It is available from nineteen suppliers. Additional details are available on the ALENDRONATE SODIUM profile page.
The generic ingredient in ALENDRONATE SODIUM is alendronate sodium. There are twenty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the alendronate sodium profile page.
The generic ingredient in ALENDRONATE SODIUM is alendronate sodium. There are twenty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the alendronate sodium profile page.
Summary for 214512
| Tradename: | ALENDRONATE SODIUM |
| Applicant: | Novitium Pharma |
| Ingredient: | alendronate sodium |
| Patents: | 0 |
Suppliers and Packaging for NDA: 214512
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ALENDRONATE SODIUM | alendronate sodium | SOLUTION;ORAL | 214512 | ANDA | ANI Pharmaceuticals, Inc. | 70954-264 | 70954-264-10 | 4 BOTTLE in 1 CARTON (70954-264-10) / 75 mL in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | EQ 70MG BASE/75ML | ||||
| Approval Date: | May 11, 2023 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
